Prodan-Bărbulescu C, Alin CD, Faur IF, Bujor GC, Şeclăman EP, Enătescu V, Dănilă AI, Dăescu E, Hajjar R, Ghenciu LA, Tuţac P, Paşca P, Cimpean AM, Duta C. Identification of Specific Plasma miRNAs as Potential Biomarkers for Major Depressive Disorder.
Biomedicines 2024;
12:2165. [PMID:
39457478 PMCID:
PMC11505153 DOI:
10.3390/biomedicines12102165]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2024] [Revised: 09/17/2024] [Accepted: 09/20/2024] [Indexed: 10/28/2024] Open
Abstract
BACKROUND
Depression is a significant concern in clinical and preclinical psychoneurobiological sciences due to its high prevalence and its individual and collective consequences. Identifying efficient biomarkers for accurate diagnosis is crucial, with ideal biomarkers having detectable serum levels and conformational and thermal stability. This study aims to identify stable plasma biomarkers for the diagnosis and prognosis of major depressive disorder, as the pathogenesis of the disorder remains incompletely understood, affecting diagnosis accuracy.
METHODS
Thus, this study included ten MDD patients and eight healthy controls. The present work analyzed miRNAs in patients with major depressive disorder compared to healthy controls.
RESULTS
Eleven specific miRNAs, particularly hsa-miR-874-3p; hsa-let-7d-5p; and hsa-miR-93-3p showed upregulation-type plasma variations in the group of patients with major depressive disorder. miRNA functionality is linked to depressive pathophysiology.
CONCLUSIONS
This study identifies a "bouquet" of miRNAs with significant upregulation variations in patients with major depressive disorder, suggesting further research to determine their suitability for personalization and evaluation, ultimately becoming integral components of major depression serological evaluations.
Collapse